From: Predictive factors for moderate or severe exacerbations in asthma patients receiving outpatient care
N = 330 | Baseline | 4 months | 8 months | 12 months |
---|---|---|---|---|
No continuing tx (on demand) | 23.3% | 9.8% | 12.6% | 9.9% |
Inhaled steroids mono-tx | 8.9% | 8.3% | 7.7% | 7.1% |
Formoterol/budesonide | 20.8 | 26.5% | 26.2% | 26.2% |
Salmeterol/fluticasone | 46.9% | 52.1% | 53.5% | 56.5% |
Montelukast | 32.4% | 40.1% | 47.9% | 50% |
Equivalent dose of inhaled steroids | 1185.5 (780.1) | 1276.6 (922.3) | 1249.3 (851.9) | 1221.5 (822.9) |
Compliance inhaled medication | ||||
Good | 74.1% | 77.1% | 85.8% | 86.3% |
Fair | 5.6% | 7.4% | 5.1% | 6.2% |
Poor | 20.3% | 15.5% | 9.2% | 7.5% |
Compliance oral medication | ||||
Good | 72% | 81.3% | 86.7% | 91.1% |
Fair | 4.8% | 2.7% | 2.8% | 2.6% |
Poor | 23.2% | 15.9% | 10.5% | 6.3% |
Inhaler technique | ||||
Correct | 74.1% | 88.7% | 92% | 96.1% |